Clinical trials: Gastrointestinal Disorders, Functional
Liver Diseases
A Research Study on Etavopivat in Participants With and Without Liver Disease
The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic function (matched controls).
- Trial name
- NCT06336018
- Testing
- Etavopivat
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Irritable Bowel Syndrome
Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome
The purpose of this study is to evaluate the safety and efficacy of different doses of asimadoline in the treatment of patients with irritable bowel syndrome.
- Trial name
- NCT00454688
- Testing
- Asimadoline
- Where
- 112 sites in United States
- Volunteers
- 596 people
- Sponsor
- Tioga Pharmaceuticals
Cystic Fibrosis
A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes
The study evaluates the long-term safety and efficacy of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) triple combination (TC) in participants with CF who are 6 years of age and older with F/MF genotypes.
- Trial name
- NCT04545515
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 34 sites in Australia, Canada and 8 more
- Volunteers
- 120 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatic Function Abnormal
A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment
In human, metabolic hepatic clearance represents a significant part of the total clearance of fexinidazole and could be decreased in patients with liver impairment, leading to some overexposure, and conversely, the formation of…
- Trial name
- NCT05607173
- Testing
- Fexinidazole (HOE239)
- Where
- 2 sites in Bulgaria, France
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Sanofi
Urinary Incontinence, Urinary Incontinence, Urge
Safety and Performance of UCon Bar Electrode for the Treatment of Overactive Bladder (OAB) and Bowel Dysfunction (BD)
UCon is a medical device for treatment of the symptoms of overactive bladder (OAB) and bowel dysfunction (BD). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder/bowel musculature…
- Conditions
- Urinary Incontinence, Urinary Incontinence, Urge, Fecal Incontinence, Fecal Incontinence With Fecal Urgency
- Trial name
- NCT06091566
- Testing
- UCon-Bar
- Where
- 3 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- InnoCon Medical
Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome Survey in Gastroenterological Adult Outpatients in China
The primary objective of this study is to estimate the overall prevalence of IBS medically diagnosed and diagnosed using Rome III or IV criteria in GI adult outpatients in China.
- Trial name
- IRONS (NCT02955316)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Irritable Bowel Syndrome, Crohn Disease
Effect of UGIR in Adults With Compromised Gut Function and Malabsorption
This study assessed the effect of a nutrition support product on quality of life in adults with compromised gut function and malabsorption.
- Conditions
- Irritable Bowel Syndrome, Crohn Disease, Ulcerative Colitis, Celiac Disease
- Trial name
- NCT03011593
- Testing
- Nutrition Support Product
- Volunteers
- 18 people
- Sponsor
- Metagenics, Inc.
Ulcerative Colitis, Crohn Disease
Microbial and Human Determinants of the Onset of IBD Flares
This is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of IBD flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata.
- Conditions
- Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated
- Trial name
- NCT05463900
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Viome
Irritable Bowel Syndrome in Females
A Safety and Efficacy Study of Daikenchuto (TU-100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome
The aim of this study is to assess the effect of orally administered TU-100 (5 g three times daily [TID]) as compared to placebo on abdominal bloating rating in female IBS patients.
- Trial name
- NCT02074579
- Testing
- TU-100
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Tsumura USA
Gastrointestinal Diseases
Gastrointestinal Myoelectric Activity Protocol, the G-Tech EEnG Protocol
A feasibility study for monitoring and recording gastrointestinal (GI) myoelectric activity in subjects with suspected or diagnosed irritable bowel syndrome (IBS) and reports of GI pain and asymptomatic subjects without IBS and…
- Trial name
- NCT01697397
- Testing
- Recording of Myoelectric Signals
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- G-Tech Corporation
Irritable Bowel Syndrome
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.
- Trial name
- NCT04880876
- Testing
- 25mg Eluxadoline, 100mg Eluxadoline
- Where
- 6 sites in United States
- Volunteers
- 124 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome (IBS)
A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers
This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time.
- Trial name
- NCT00401479
- Testing
- Solabegron (GW427353)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline